Analysing molecular polar surface descriptors to predict blood-brain barrier permeation

Molecular polar surface (PS) descriptors are very useful parameters in prediction of drug transport properties. They could be also used to investigate the blood-brain barrier (BBB) permeation rate for various chemical compounds. In this study, a dataset of drugs (n = 19) from various pharmacological groups was studied to estimate their potential properties to permeate across the BBB. Experimental logBB data were available as steady-state distribution values of the in vivo rat model for these molecules. Including accurate calculation of the electrostatic potential maps, polar surface descriptors, such as a two-dimensional polar surface area (2D-PSA), topological polar surface area (TPSA) and three-dimensional polar surface area or polar area (3D-PSA; PA) were measured and analysed. We report the strong correlation of these descriptors with logBB values for the prediction of BBB permeation using the linear partial least squares (PLS) fitting technique. The 3D-PSA descriptor showed the best fit to logBB values with R² = 0.92 and RMSD = 0.29 (p-value < 0.0001). The obtained results demonstrate that all descriptors bear high predictive powers and could provide an efficient strategy to envisage the pharmacokinetic properties of chemical compounds to permeate across the BBB at an early stage of the drug development process.

[1]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[2]  W. Geldenhuys,et al.  3-D-QSAR and docking studies on the neuronal choline transporter. , 2010, Bioorganic & medicinal chemistry letters.

[3]  Kazuhiko Yanai,et al.  In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[5]  J. Baron,et al.  A comprehensive investigation of plasma and brain regional pharmacokinetics of imipramine and its metabolites during and after chronic administration in the rat. , 1996, Journal of pharmaceutical sciences.

[6]  Ulf Norinder,et al.  Prediction of Polar Surface Area and Drug Transport Processes Using Simple Parameters and PLS Statistics. , 2001 .

[7]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[8]  E. Spina,et al.  ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety , 2008, Therapeutic drug monitoring.

[9]  Kristina Luthman,et al.  Polar Molecular Surface Properties Predict the Intestinal Absorption of Drugs in Humans , 1997, Pharmaceutical Research.

[10]  Hyosub E. Kim,et al.  A Comparative Study of Successful Central Nervous System Drugs Using Molecular Modeling , 2011 .

[11]  N. Nachtrieb,et al.  Principles of Modern Chemistry , 1986 .

[12]  Nipa Shah,et al.  Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. , 2009, Molecular pharmaceutics.

[13]  J. Donovan,et al.  The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. , 2004, The international journal of neuropsychopharmacology.

[14]  W. Pardridge,et al.  Drug Transport across the Blood–Brain Barrier , 2012, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  R Griffiths,et al.  Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. , 1988, Journal of medicinal chemistry.

[17]  Bernard Testa,et al.  A simple model to predict blood-brain barrier permeation from 3D molecular fields. , 2002, Biochimica et biophysica acta.

[18]  M. Ingelman-Sundberg,et al.  Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles. , 2005, Toxicology in vitro : an international journal published in association with BIBRA.

[19]  Imre G. Csizmadia,et al.  Theory and Practice of MO Calculations on Organic Molecules , 1976 .

[20]  G. Fricker Drug transport across the blood-brain barrier. , 2002, Ernst Schering Research Foundation workshop.

[21]  Guo-Ping Wang,et al.  Predicting blood-brain barrier penetration from molecular weight and number of polar atoms. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[22]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[23]  M. Dove An introduction to atomistic simulation methods , 2008 .

[24]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[25]  M. Ebinger,et al.  Blood-brain barrier penetration and pharmacokinetics of amitriptyline and its metabolites in p-glycoprotein (abcb1ab) knock-out mice and controls. , 2007, Journal of psychiatric research.

[26]  D. E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. , 1999, Journal of pharmaceutical sciences.

[27]  R. J. Doerksen,et al.  Topological polar surface area: a useful descriptor in 2D-QSAR. , 2009, Current medicinal chemistry.

[28]  A. Leo,et al.  Hydrophobicity and central nervous system agents: on the principle of minimal hydrophobicity in drug design. , 1987, Journal of pharmaceutical sciences.

[29]  Zeruesenay Desta,et al.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. , 2004, British journal of clinical pharmacology.

[30]  D. E. Clark,et al.  Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. , 1999, Journal of pharmaceutical sciences.

[31]  D. Greenblatt,et al.  Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[32]  Yuichi Sugiyama,et al.  Impact of Drug Transporter Studies on Drug Discovery and Development , 2003, Pharmacological Reviews.

[33]  C. Ebert,et al.  Volsurf computational method applied to the prediction of stability of thermostable enzymes. , 2007, Biotechnology journal.

[34]  Warren J. Hehre,et al.  A Guide to Molecular Mechanics and Quantum Chemical Calculations , 2003 .

[35]  Colin D. A. Brown,et al.  Mediation of cimetidine secretion by P‐glycoprotein and a novel H+‐coupled mechanism in cultured renal epithelial monolayers of LLC‐PK1 cells , 1996, British journal of pharmacology.

[36]  L. Rubin,et al.  Occludin as a possible determinant of tight junction permeability in endothelial cells. , 1997, Journal of cell science.

[37]  M. Pirmohamed,et al.  Carbamazepine is not a substrate for P-glycoprotein. , 2001, British journal of clinical pharmacology.

[38]  R. H. Petrucci,et al.  General Chemistry: Principles and Modern Applications , 1972 .

[39]  W. Löscher,et al.  Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein , 2007, Neuropharmacology.